GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » Return-on-Tangible-Asset

FBRX (Forte Biosciences) Return-on-Tangible-Asset : -152.50% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Forte Biosciences's annualized Net Income for the quarter that ended in Sep. 2024 was $-33.57 Mil. Forte Biosciences's average total tangible assets for the quarter that ended in Sep. 2024 was $22.01 Mil. Therefore, Forte Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 was -152.50%.

The historical rank and industry rank for Forte Biosciences's Return-on-Tangible-Asset or its related term are showing as below:

FBRX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -104.96   Med: -58.72   Max: -32.54
Current: -104.96

During the past 4 years, Forte Biosciences's highest Return-on-Tangible-Asset was -32.54%. The lowest was -104.96%. And the median was -58.72%.

FBRX's Return-on-Tangible-Asset is ranked worse than
78.91% of 1503 companies
in the Biotechnology industry
Industry Median: -39.32 vs FBRX: -104.96

Forte Biosciences Return-on-Tangible-Asset Historical Data

The historical data trend for Forte Biosciences's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forte Biosciences Return-on-Tangible-Asset Chart

Forte Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
-75.91 -41.53 -32.54 -77.74

Forte Biosciences Quarterly Data
Sep19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.73 -54.08 -83.61 -172.28 -152.50

Competitive Comparison of Forte Biosciences's Return-on-Tangible-Asset

For the Biotechnology subindustry, Forte Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Forte Biosciences's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forte Biosciences's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Forte Biosciences's Return-on-Tangible-Asset falls into.



Forte Biosciences Return-on-Tangible-Asset Calculation

Forte Biosciences's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-31.476/( (41.997+38.98)/ 2 )
=-31.476/40.4885
=-77.74 %

Forte Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=-33.568/( (26.078+17.946)/ 2 )
=-33.568/22.012
=-152.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2024) net income data.


Forte Biosciences  (NAS:FBRX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Forte Biosciences Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Forte Biosciences Business Description

Traded in Other Exchanges
N/A
Address
3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
Executives
Antony A Riley officer: Chief Financial Officer C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Paul A. Wagner director, officer: See Remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska director 749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen officer: See remarks C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein director 129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck director C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Thomas E Darcy director C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams director C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Steven Kornfeld director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Lawrence Eichenfield director C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Steven Michael Oliveira 10 percent owner 18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar officer: SVP Clinical Development C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Faheem Hasnain director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142